Abstract
The interest that surrounds the bacterium Helicobacter pylori (H. pylori) is due not only to its causal role in several gastroduodenal diseases, but also to its supposed involvement in the pathogenesis of extra-gastric manifestations. This review provides a literature update on the hypothetic correlation between H. pylori and headache. To identify all publications on this issue, a MEDLINE search of all studies published in English from 1965 to 2013 was conducted. The authors examined three aspects of this potential association: epidemiology, intervention trials and pathogenesis. While in the former, the results are contradictory, in the intervention studies, it has been documented that at 6 and 12 months, bacterial eradication is associated to disappearance of symptoms in 23% and 28% of cases, and to a significant decrease of intensity, frequency and duration of acute attacks in the remaining patients. Under a pathogenetic aspect, if H. pylori has a role, it does not act through oxidative stress. In conclusion, the eradication of H. pylori seems efficient at least in a subgroup of patients suffering from migraine. Further investigations should focalize on particular subgroups of patients and, encouraged from data produced by intervention studies, evaluate the long-term benefit of eradication.
Keywords: Antimicrobials, antisecretive drugs, headache, Helicobacter pylori, migraine.
Infectious Disorders - Drug Targets
Title:Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Volume: 13 Issue: 5
Author(s): Lidia Savi, Davide G. Ribaldone, Sharmila Fagoonee and Rinaldo Pellicano
Affiliation:
Keywords: Antimicrobials, antisecretive drugs, headache, Helicobacter pylori, migraine.
Abstract: The interest that surrounds the bacterium Helicobacter pylori (H. pylori) is due not only to its causal role in several gastroduodenal diseases, but also to its supposed involvement in the pathogenesis of extra-gastric manifestations. This review provides a literature update on the hypothetic correlation between H. pylori and headache. To identify all publications on this issue, a MEDLINE search of all studies published in English from 1965 to 2013 was conducted. The authors examined three aspects of this potential association: epidemiology, intervention trials and pathogenesis. While in the former, the results are contradictory, in the intervention studies, it has been documented that at 6 and 12 months, bacterial eradication is associated to disappearance of symptoms in 23% and 28% of cases, and to a significant decrease of intensity, frequency and duration of acute attacks in the remaining patients. Under a pathogenetic aspect, if H. pylori has a role, it does not act through oxidative stress. In conclusion, the eradication of H. pylori seems efficient at least in a subgroup of patients suffering from migraine. Further investigations should focalize on particular subgroups of patients and, encouraged from data produced by intervention studies, evaluate the long-term benefit of eradication.
Export Options
About this article
Cite this article as:
Savi Lidia, Ribaldone G. Davide, Fagoonee Sharmila and Pellicano Rinaldo, Is Helicobacter pylori the Infectious Trigger for Headache?: A Review, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526513666131201125021
DOI https://dx.doi.org/10.2174/1871526513666131201125021 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Prevalence, Morbidities, and Treatments of Insomnia
CNS & Neurological Disorders - Drug Targets Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi
Current Medicinal Chemistry Future Challenges for Microsomal Transport Protein Inhibitors
Current Vascular Pharmacology Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options
Current Pharmaceutical Design Long-term Reproductive and Metabolic Consequences of PCOS
Current Diabetes Reviews Antitumor Activity of Magnetite Nanoparticles: Influence of Hydrocarbonated Chain of Saturated Aliphatic Monocarboxylic Acids
Current Organic Chemistry Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Medication Management for People with Dementia or Cognitive Impairment)
Current Clinical Pharmacology Optimization and Assay of Antioxidant Potential of Two Penicillium spp. by Different Procedures
Current Biotechnology Cyanosis Due to Methemoglobinemia Induced by Topical Anesthesia in a Premature Infant
Current Drug Therapy Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Clinical Application of Ghrelin
Current Pharmaceutical Design